Fatty liver index as an independent predictor of all-cause and disease-specific mortality

Ruixin Zhang,Shuhao Ren,Hongfei Mi,Meixia Wang,Tingjuan He,Renyan Zhang,Wei Jiang,Chenghao Su
DOI: https://doi.org/10.1097/meg.0000000000002865
2024-10-31
European Journal of Gastroenterology & Hepatology
Abstract:Nonalcoholic fatty liver disease (NAFLD) is estimated to have a global prevalence of approximately 30% [ 1 ] and has become the leading cause of chronic liver disease worldwide [ 2 ]. A rapid increase in the incidence and mortality of NAFLD occurred across all age groups and in 80% of countries worldwide from 1990 to 2019, highlighting a significant public health concern [ 3 ]. In 2023, multinational liver societies introduced the term metabolic dysfunction-associated steatotic liver disease (MASLD) to replace NAFLD, addressing concerns about the exclusionary nature of the previous diagnosis and the potential for stigmatization [ 4 ]. Given that this study pertains to the diagnosis of NAFLD, the term NAFLD will primarily be used. The term MASLD will be employed in contexts where it is specifically relevant.
gastroenterology & hepatology
What problem does this paper attempt to address?